Anti-Infective Start-Ups See Opportunity In An Epidemiological Nightmare
This article was originally published in Start Up
Executive Summary
Infectious disease researchers have been warning for decades of the growing numbers of drug-resistant bacteria, and a certain subset of investors and companies sees this epidemiological nightmare as an alluring business opportunity. We profile three emerging anti-infective drug developers in this issue: Arsanis Biosciences, ContraFect, and Fedora Pharmaceuticals.
You may also be interested in...
Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing
Chinese-U.S. hybrid MicuRx, founded by Vicuron veterans, has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.
Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing
A six-year-old start-up founded by Vicuron veterans has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.
The Regulatory Pendulum Swings In Favor Of Antibiotics, But Will Investments Follow?
New incentives under the US government’s GAIN Act and FDA’s openness to faster development are helping put antibiotics back on investors’ radar screens, if not yet loosening their checkbooks.